The 2016 ACC/AHA Guideline Focused Update on Duration of DAPT in Patients with coronary artery disease recommended an indefinite aspirin dose of 81 mg in combination with varying durations of P2Y12 inhibitors depending on the situation (acute coronary syndrome vs. stable ischemic heart disease), treatment (medical, lytic, PCI, and/or CABG), and bleeding risk with a brief reference to limited duration triple therapy as necessary [53]. The gene discussed is P2RY12; the disease is coronary artery disorder.